ARC has reported its Motherlabs are 60 per cent occupied within two months of their birth.

The flexible, serviced accelerator space, designed for growing science, tech and innovation operators occupiers, is seeing high levels of demand.

Sania Therapeutics, Epsilogen and GENinCode all took space recently and ARC has plans to grow Motherlabs further across its 1.6 million sq ft cluster network, including Harwell, and Oxford.

The concept offers a flexible, short lease structure, managed private labs and write-up spaces with shared facilities and dedicated lab manager, designed to help its occupiers grow sustainably while taking ideas from concept, then to lab and to commercialisation at speed.

Daniel Pagella, ARC senior director, said: “Science plays a huge role in our everyday lives and is vital in tackling the global challenges that we face from the pandemic to the climate emergency. Providing the right space and ecosystem, and reducing barriers to growth, is key to unleashing the transformative potential of our world class science and innovation base.”

Dr Andrew Murray, chief executive and co-founder of Sania Therapeutics, which has taken Motherlabs space at ARC West London, said: “A major bottleneck in the London biotechnology space is the supply of high-quality laboratories.

“Motherlabs addresses that problem and more by not only providing space, but also the services, shared facilities and general collaborative environment that allows biotech companies to develop. We are excited to be part of Motherlabs and Sania looks forward to growing alongside them.”

© Thames Tap (powered by

Sign up to receive your free weekly Thames Tap journal here.